Skip to main content

Table 4 Reduction in V20 (%) using different PTV definitions.

From: A dosimetric analysis of respiration-gated radiotherapy in patients with stage III lung cancer

  V20 (%) Absolute V20 (%) and relative (%) reduction in V20
Patient PTVroutine PTVall phases vs. PTVroutine PTVgating vs. PTVroutine PTVgating vs. PTVall phases
1 38.0 4.1 (10.8%) 5.1 (13.4%) 1.0 (2.9%)
2 27.1 2.2 (8.1%) 3.5 (12.9%) 1.3 (5.2%)
3 29.0 2.0 (6.9%) 2.8 (9.7%) 0.8 (3.0%)
4 31.0 3.8 (12.3%) 6.7 (21.6%) 2.9 (10.7%)
5 26.1 2.2 (8.4%) 2.9 (11.1%) 0.7 (2.9%)
6 28.9 -1.5 (-5.2%) 0.1 (0.3%) 1.6 (5.3%)
7 26.2 0.9 (3.4%) 4.3 (16.4%) 3.4 (13.4%)
8 20.5 3.7 (18%) 4.4 (21.5%) 0.7 (4.2%)
9 28.2 1.7 (6.0%) 4.8 (17.0%) 3.1 (11.7%)
10 27.5 4.2 (15.3%) 6.5 (23.6%) 2.3 (9.9%)
11 27.6 2.4 (8.7%) 4.9 (17.8%) 2.5 (9.9%)
12 25.5 4.4 (17.3%) 4.9 (19.2%) 0.5 (2.4%)
13 28.8 2.9 (10.1%) 6.0 (20.8%) 3.1 (12.0%)
14 23.9 3.7 (15.5%) 4.2 (17.6%) 0.5 (2.5%)
15 42.8 5.0 (11.7%) 8.6 (20.1%) 3.6 (9.5%)
Mean 28.7 2.8 (9.8%) 4.6 (16.2%) 1.9 (7.0%)
SD 5.4 1.7 (5.9%) 2.0 (6.0%) 1.2 (4.1%)